4//SEC Filing
Shire Human Genetic Therapies, Inc. 4
Accession 0001395064-20-000084
CIK 0001693415other
Filed
Jun 4, 8:00 PM ET
Accepted
Jun 5, 9:52 AM ET
Size
7.4 KB
Accession
0001395064-20-000084
Insider Transaction Report
Form 4
Shire Human Genetic Therapies, Inc.
10% Owner
Transactions
- Sale
Common Stock
2020-06-03$19.75/sh−40,086$791,699→ 6,824,992 total
Footnotes (3)
- [F1]Weighted average of sales prices. Actual prices range from $19.11 to $20.00. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.
- [F2]This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited.
- [F3]These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities.
Documents
Issuer
Translate Bio, Inc.
CIK 0001693415
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001745009
Filing Metadata
- Form type
- 4
- Filed
- Jun 4, 8:00 PM ET
- Accepted
- Jun 5, 9:52 AM ET
- Size
- 7.4 KB